ImmuPharma Plc logo

ImmuPharma Plc(LSE) IMM

Market Cap£20.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2006)-94%
5 Year-57%
1 Year-74%
1 Month-6%
£0.03
-5.71%
-0.00Today
ImmuPharma Plc last closing stock price
MetricPriceDate
Last closeGBX 3.302026-10-02
ImmuPharma Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.92%GBX 3.272026-09-25
1 month-5.98%GBX 3.512026-09-02
3 month-5.17%GBX 3.482026-07-03
Year to date-46.77%GBX 6.202025-12-31
1 year-73.71%GBX 12.552025-10-02
3 year+83.33%GBX 1.802023-10-03
5 year-56.81%GBX 7.642021-10-01
Since inception-93.77%GBX 0.532006-02-22

ImmuPharma Plc Financials at a Glance

Market Cap

£20.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£0.00

Net Income (TTM)

-£7.02M

EPS (TTM)

-£0.01

P/E Ratio

-3.93

Dividend

£0.00

Beta (Volatility)

-0.04 (Low)

Price

£0.03

Volume

2,991,040

Open

£0.03

Previous Close

£0.03

Daily Range

£0.03 - £0.04

52-Week Range

£0.03 - £0.14

Estimated Earnings Date

May 25, 2027

IMM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ImmuPharma Plc

ImmuPharma PLC is a biopharmaceutical company based in the United Kingdom, specializing in the discovery and development of peptide-based therapeutics. The company focuses on addressing unmet medical needs in the areas of autoimmunity, inflammation, and anti-infectives.

Products and Services
  • Lead product candidate P140 targets autoimmune diseases
  • BioAMB for serious fungal infections
  • Collaboration with Centre National de la Recherche Scientifique for peptide technology
Growth Outlook
  • P140 is in Phase III trials for systemic lupus erythematosus
  • Expansion into chronic inflammatory demyelinating polyneuropathy with Phase II trials
  • Potential for additional indications including asthma and irritable bowel disease
Financial Highlights
  • Recent quarterly revenue of 0, reflecting ongoing R&D focus
  • Cash and cash equivalents of £1,352,249 as of Q4 2025
  • Net income of £31,214 in Q4 2025, indicating operational adjustments
ImmuPharma PLC is positioned in a niche market with its innovative peptide-based therapies. The company’s lead candidate, P140, is undergoing critical clinical trials, which could significantly impact its future revenue streams. The focus on autoimmune diseases and inflammation aligns with growing healthcare needs, potentially leading to substantial market opportunities. Financially, while the company has not generated revenue recently, it maintains a solid cash position, allowing for continued investment in research and development. The strategic collaborations and ongoing clinical trials suggest a commitment to advancing its product pipeline, which may attract investor interest as the company progresses through its clinical phases.
AI Generated • Sep 13, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Tim McCarthy McCarthy, MBA

Website

www.immupharma.com

Headquarters

London, GL EC1A 7BL, GB

IMM Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-559.87%

Return on Capital

-370.19%

Return on Assets

-226.67%

Earnings Yield

-25.45%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£20.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

623.91M

Volume

2.99M

Avg. Volume

1.59M

Financials (TTM)

Gross Profit

-£7.27K

Operating Income

-£2.29M

EBITDA

-£3.55M

Operating Cash Flow

-£2.76M

Capital Expenditure

-£3.63K

Free Cash Flow

-£2.77M

Cash & ST Invst.

£695.84K

Total Debt

£0.00

ImmuPharma Plc Performance Analysis

ImmuPharma Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 0N/A
20232023-12-31GBP 0N/A
20242024-12-31GBP 0N/A
20252025-12-31GBP 0N/A
ImmuPharma Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
ImmuPharma Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP -0.01-61.2%
20232023-12-31GBP -0.01-35.7%
20242024-12-31GBP -0.01-25.9%
20252025-12-31GBP -0.00-38.3%
ImmuPharma Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30100.0%
Q42025-12-31N/A
Q12026-03-31-4300.0%
Q22026-06-30-100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

£0.00

N/A

Gross Profit

-£497.00

+98.3%

Gross Margin

0.00%

N/A

Market Cap

£20.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£2.94M

N/A

Employees

7

N/A

Net Income

-£4.70M

-411.6%

EBITDA

-£1.07M

-77.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

£695.84K

+75.4%

Total Debt

£0.00

N/A

Accounts Receivable

£294.10K

+89.3%

Inventory

£0.00

N/A

Long Term Debt

£0.00

N/A

Short Term Debt

£0.00

N/A

Return on Assets

-2.27%

N/A

Return on Invested Capital

-1.26%

N/A

Free Cash Flow

-£477.44K

+5.0%

Operating Cash Flow

-£476.67K

+5.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SBTX.LSkinBioTherapeutics Plc
£0.06+0.00%
HVO.LhVIVO plc
£0.06-1.64%
HEMO.LHemogenyx Pharmaceuticals Plc
£6.50+20.37%
CREO.LCreo Medical Limited
£0.10-1.53%

Trending Stocks

Symbol / CompanyPricePrice Chg
NKENike
$33.87-3.64%
NVDANvidia
$233.95+1.34%
SPCXSpace Exploration Technologies
$158.96+7.36%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$29.71-6.46%

Questions About IMM

What is the current price of ImmuPharma Plc?

ImmuPharma Plc is trading at £0.03 per share.

What is the 52-week range for ImmuPharma Plc?

Over the past 52 weeks, ImmuPharma Plc has traded between £0.03 and £0.14.

How much debt does ImmuPharma Plc have?

As of the most recent reporting period, ImmuPharma Plc reported total debt of £0.00.

How much cash does ImmuPharma Plc have on hand?

ImmuPharma Plc reported £1.35M in cash and cash equivalents in its most recent financial results.

What is ImmuPharma Plc’s dividend yield?

ImmuPharma Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services